JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Sotera Health (NASDAQ:SHC) Stock

Key Points

• JPMorgan raised Sotera Health’s price target from $16 to $18 but maintained a neutral rating, implying roughly 4.7% downside from the reported share price of $18.89.
• Analyst sentiment remains broadly positive: eight analysts rate the stock Buy and three rate it Hold, producing a “Moderate Buy” consensus and an average price target of $20.50.
• Sotera Health exceeded quarterly expectations, reporting $0.26 EPS and $321.4 million in revenue, while revenue grew 9.2% year over year; the company also issued fiscal 2026 EPS guidance of $0.95–$1.01.

Sotera Health (NASDAQ:SHC - Get Free Report) had its price target lifted by equities research analysts at JPMorgan Chase & Co. from $16.00 to $18.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s price target points to a potential downside of 4.69% from the stock's current price.

SHC has been the topic of several other reports. Barclays reaffirmed an "overweight" rating on shares of Sotera Health in a report on Friday. Citigroup restated a "buy" rating on shares of Sotera Health in a research report on Friday. The Goldman Sachs Group assumed coverage on shares of Sotera Health in a report on Friday, June 5th. They issued a "buy" rating and a $20.00 price target on the stock. UBS Group set a $19.00 price objective on Sotera Health in a research note on Wednesday, June 24th. Finally, Weiss Ratings upgraded Sotera Health from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, July 9th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $20.50.

Sotera Health Stock Performance

Shares of SHC traded down $0.03 during trading hours on Friday, reaching $18.89. 1,028,071 shares of the company traded hands, compared to its average volume of 2,867,321. The stock has a market capitalization of $5.39 billion, a P/E ratio of 45.99 and a beta of 1.77. The company has a quick ratio of 2.54, a current ratio of 2.82 and a debt-to-equity ratio of 3.56. Sotera Health has a 12-month low of $12.94 and a 12-month high of $19.85. The business has a fifty day moving average price of $17.07 and a 200-day moving average price of $16.31.

Sotera Health (NASDAQ:SHC - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.02. Sotera Health had a return on equity of 39.73% and a net margin of 9.91%.The firm had revenue of $321.38 million for the quarter, compared to the consensus estimate of $309.70 million. During the same period in the prior year, the firm earned $0.20 EPS. The firm's revenue was up 9.2% on a year-over-year basis. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Equities analysts anticipate that Sotera Health will post 0.87 EPS for the current fiscal year.

Insider Activity at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $15.17, for a total value of $193,194,516.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 15.36% of the company's stock.

Institutional Investors Weigh In On Sotera Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in SHC. Sculptor Capital LP boosted its holdings in shares of Sotera Health by 57.4% during the 4th quarter. Sculptor Capital LP now owns 21,000,000 shares of the company's stock worth $370,440,000 after purchasing an additional 7,658,200 shares during the last quarter. Sachem Head Capital Management LP grew its holdings in Sotera Health by 47.2% in the 4th quarter. Sachem Head Capital Management LP now owns 11,645,000 shares of the company's stock valued at $205,418,000 after buying an additional 3,735,000 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Sotera Health by 16.7% in the 4th quarter. Vanguard Group Inc. now owns 19,228,375 shares of the company's stock worth $339,189,000 after acquiring an additional 2,756,583 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Sotera Health by 1,206.2% during the 4th quarter. AQR Capital Management LLC now owns 2,864,106 shares of the company's stock worth $50,523,000 after acquiring an additional 2,644,831 shares during the period. Finally, Norges Bank acquired a new position in shares of Sotera Health during the 4th quarter valued at about $45,278,000. Institutional investors and hedge funds own 91.03% of the company's stock.

Key Sotera Health News

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Second-quarter revenue rose 9.2% year over year to $321.4 million, ahead of the $309.7 million consensus estimate. Adjusted EPS was $0.26, topping expectations of $0.24 and increasing from $0.20 a year earlier. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Profitability improved significantly: GAAP net income increased to $53.6 million from $8.0 million, while adjusted EBITDA grew 10% and the adjusted EBITDA margin expanded to 51.6%.
• Positive Sentiment: Growth was broad-based. Sterigenics revenue increased 7.0% on a constant-currency basis, Nordion grew 16.7%, and Nelson Labs rose 5.4%. Nordion also delivered a 160-basis-point improvement in segment margin.
• Positive Sentiment: Sotera Health raised its 2026 outlook, now expecting constant-currency revenue growth of 5.25% to 6.75%, adjusted EBITDA growth of 5.75% to 7.25%, and adjusted EPS of $0.95 to $1.01 versus the prior midpoint of expectations. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Balance-sheet trends improved modestly. Net leverage declined to 3.0x, within the company’s long-term target range, liquidity reached approximately $950 million, and a term-loan repricing is expected to reduce annual interest expense by about $3.5 million.
• Neutral Sentiment: The earnings call highlighted confidence in demand for Sotera Health’s mission-critical sterilization, isotope and laboratory-testing services, but future results remain dependent on supply availability, inflation, foreign exchange and execution across its business units. Sotera Health Q2 2026 Earnings Call Transcript
• Negative Sentiment: Total debt remained high at approximately $2.2 billion. Investors also continue to face litigation, regulatory and reputational risks tied to ethylene oxide emissions, while higher costs pressured Nelson Labs’ first-half segment income.

Sotera Health Company Profile

Sotera Health Inc NASDAQ: SHC is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source